[ad_1]
DUBLIN, June 10, 2022 /PRNewswire/ — The “Graft Versus Host Disease (GvHD) Treatment Market Forecast – Epidemiology & Pipeline Analysis 2022-2027” report has been added to ResearchAndMarkets.com’s offering.
The report considers the present scenario of the graft versus host disease market and its market dynamics for the period 2022-2027. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the market. It also profiles and analyses leading companies and several other prominent companies operating in the market.
The graft versus host disease market to grow at a CAGR of 7.44% during 2021-2027.
SEGMENT ANALYSIS
- Corticosteroids accounted for the significant share of more than 28.97% in the global GvHD treatment market due to its wide recommendation in front line setting.
- The acute GVHD (aGVHD) accounted for a significant share of 34.73% in the global graft versus host disease (GVHD) treatment market due to 30% to 50% of hematopoietic stem cell transplant recipients develop acute GVHD.
- Males are accounted for the significant share of 59.64% in the global GvHD treatment market due to rise in number of hematopoietic stem cell transplantations.
Key Report Features:
- Detailed overview of GVHD, including disease definition, classification, diagnosis, and treatment pattern
- Overview of the global graft versus host disease treatment market trends in the eight major markets (8MM)
- Historical, …
Full story available on Benzinga.com
[ad_2]
Source link
